7

Listed companies

16

Private companies

51

Insiders

Relation chart of related listed companies: Capricor Therapeutics, Inc.

Active Relations

Past Relations

Relationship chart for related private companies: Capricor Therapeutics, Inc.

Active Relations

Past Relations

Related private companies: Capricor Therapeutics, Inc.

Two River Group Holdings LLC

Investment Managers

Kirax Corp.

Pharmaceuticals: Major

Riverbank Capital Securities, Inc.

Investment Banks/Brokers

Cardiovascular Research Foundation

Miscellaneous Commercial Services

Two River Group Management LLC

Two Rivers Consulting Corp.

V-Wave Ltd.

Medical Specialties

Vida Ventures LLC

Investment Managers

VV Manager LLC

Investment Managers

ByHeart, Inc.

Food: Meat/Fish/Dairy

105 W First Street LLC

Real Estate Investment Trusts

Breakthrough Properties LLC

Investment Managers

Breakthrough Services LLC

D3C1 Allston Co-Investment LP

Financial Conglomerates

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Biotechnology5
Investment Managers4
Pharmaceuticals: Major3
Miscellaneous Commercial Services2
Medical Specialties2
Financial Conglomerates1
Real Estate Investment Trusts1
Investment Banks/Brokers1
Food: Meat/Fish/Dairy1

Countries of related companies

United States21
Canada1
Israel1
Logo Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Employees
231